09 Jun 2026

CRC Research Update — June 09, 2026

Creator: The CRC Digest
Published: 2026-06-09T14:07:48Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Phase 3 trial finds post-adjuvant ctDNA-guided chemotherapy does not extend survival in resected CRC
The ALTAIR trial randomly assigned 243 patients who became ctDNA-positive after completing standard adjuvant therapy to receive trifluridine/tipiracil or placebo; the treatment did not significantly prolong disease-free survival compared with placebo. (Nature Medicine)
Network meta-analysis compares long-term effectiveness of CRC screening methods
A systematic review and network meta-analysis evaluated the 10-year effects of colonoscopy, flexible sigmoidoscopy, FIT, and gFOBT on CRC incidence, mortality, and all-cause mortality in average-risk adults. (Therapeutic Advances in Gastroenterology)
Real-world study compares TKIs versus rechallenge chemotherapy in third-line mCRC
In 107 mCRC patients receiving third-line therapy, researchers compared regorafenib/fruquintinib (n=53) versus rechallenge chemotherapy (n=54) for overall survival and progression-free survival. (Clinical Oncology)
Single-cell analysis identifies epithelial cell fate signature predicting liver metastasis risk
Researchers integrated single-cell RNA sequencing of paired liver metastasis tissues to define an epithelial cell fate gene signature, then projected it onto 433 primary CRC cases to establish a predictive model for liver metastasis. (Journal of Translational Medicine)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Long-term screening effectiveness compared across modalities
Network meta-analysis of randomized trials compared colonoscopy, flexible sigmoidoscopy, FIT, and gFOBT for 10-year CRC outcomes in average-risk adults.
Machine learning predicts pathological upgrading in colorectal polyps
A study of 593 patients used explainable machine learning to stratify preoperative risk of pathological upgrading in colorectal polyps, with implications for screening optimization.

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

ctDNA-positive patients after adjuvant therapy studied in phase 3 trial
ALTAIR trial enrolled 243 patients who became ctDNA-positive after standard adjuvant therapy; trifluridine/tipiracil did not significantly improve disease-free survival versus placebo.
Germline versus somatic RNF43 mutations show different risk patterns
Analysis of 49,823 CRC/polyp cases and 165,250 controls found germline N-terminal RNF43 variants confer higher CRC risk, while C-terminal variants showed no increased risk in case-control analyses.

Stay informed as research continues to refine our understanding of CRC biology, screening, and treatment strategies.

CRC Research Update

Subscribe to The CRC Digest